<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373019</url>
  </required_header>
  <id_info>
    <org_study_id>CC-RD1</org_study_id>
    <nct_id>NCT03373019</nct_id>
  </id_info>
  <brief_title>Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
  <official_title>A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to evaluate therapeutic efficacy of Chidamide combined
      with R-GDP （rituximab/gemcitabine/dexamethasone/cisplatin）in treating Patients with relapsed
      or refractory Diffuse Large B-cell Lymphoma (DLBCL) not suitable for transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment outcome of patients with relapsed or refractory Diffuse Large B-cell Lymphoma
      (DLBCL) are not satisfactory especially for those not suitable for transplantation. One of
      main reason is chemotherapy resistance. The investigators conducted this study to evaluate
      the efficacy of Chidamide combined with R-GDP(rituximab/gemcitabine/dexamethasone/cisplatin)
      in treating patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) not
      suitable for transplantation. Chidamide is a novel benzamide type of subtype-selective
      histone deacetylase (HDAC) inhibitor. It has been approved by China Food and Drug
      Administration (CFDA) for treatment of relapsed or refractory peripheral T-cell lymphoma
      (PTCL) in Chinese population. The investigators' pre-clinical data suggested that this agent
      might be also efficient in the treatment of relapsed/refractory B cell lymphoma. In this
      open-label, non-randomized, phase II study, the investigators aimed to observe the efficacy
      and safety of chidamide combined with R-GDP in patients with relapsed or refractory Diffuse
      Large B-cell Lymphoma (DLBCL) not suitable for transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 21, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>6 weeks</time_frame>
    <description>overall response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR</measure>
    <time_frame>6 weeks</time_frame>
    <description>complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 year PFS</measure>
    <time_frame>3 years</time_frame>
    <description>3 year progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>throughout the treatment period，up to 6 months</time_frame>
    <description>adverse event related to treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Chidamide</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Neoplasm by Histology</condition>
  <condition>Neoplasms</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <condition>Lymphatic Diseases</condition>
  <condition>Immunoproliferative Disorders</condition>
  <condition>Immune System Diseases</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Cyclophosphamide</condition>
  <condition>Rituximab</condition>
  <condition>Gemcitabine</condition>
  <condition>Cisplatin</condition>
  <condition>Dexamethasone</condition>
  <condition>HDAC Inhibitor</condition>
  <arm_group>
    <arm_group_label>Chidamide combined with R-GDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide combined with R-GDP</intervention_name>
    <description>Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off</description>
    <arm_group_label>Chidamide combined with R-GDP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages: 18-75 years old

          2. Relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) previous treated with
             standard chemoimmunotherapy

          3. Not willing or not suitable for hematopoietic stem cell transplantation (HSCT)

          4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) index &lt; 2

          5. Informed consent available

          6. Life expectancy of more than 3 months;

          7. Ultrasonic cardiogram showed left ventricle ejection fraction ≥ 50%, EKG showed on
             signs of myocardial ischemia, with no previous arrhythmia which need pharmacological
             intervention.

          8. Bone marrow function: ANC ≥ 1.5 × 109/L, PLT ≥ 100 × 109/L, Hb ≥ 80g/L;

          9. Liver function: total bilirubin, ALT and AST were &lt;1.5 × UNL (the upper limit of
             normal value)

         10. Renal function: Cr&lt;1.5 × UNL and creatinine clearance &gt; 50ml/min

        Exclusion Criteria:

          1. Prior history of treatment of HDAC inhibitor.

          2. Plan of HSCT in the future

          3. Significant pericardial effusion showed by chest CT scan

          4. Prior history of other cancers except treated cervical or basal cell skin carcinoma,
             organ transplantation

          5. Syphilis or human immunodeficiency virus (HIV) infection

          6. Pregnant or lactating women

          7. History of organ transplantation

          8. Serious active infections (including hepatitis)

          9. Serious neurological or psychiatric history, including dementia or epilepsy.

        Termination criteria:

          1. Withdrew consent

          2. Researchers think it is necessary to terminate the study;

          3. Disease progression or death;

          4. Poor compliance

          5. Subclinical or clinical cardiac toxicity;

          6. Unable to continue treatment because of severe toxicity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kai Xue, MD</last_name>
    <phone>13818659448</phone>
    <email>xuekaishanghai@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kai Xue</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Xue, MD</last_name>
      <phone>13818659448</phone>
      <email>xuekaishanghai@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kai Xue</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Xue, MD</last_name>
      <phone>13818659448</phone>
      <email>xuekaishanghai@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Junning Cao, MD</last_name>
      <phone>13818659448</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kai Xue, MD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>chidamide</keyword>
  <keyword>R-GDP</keyword>
  <keyword>diffuse large B-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Lymphatic Diseases</mesh_term>
    <mesh_term>Immunoproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

